-
公开(公告)号：AU2019344300A1
公开(公告)日：2021-04-22
申请号：AU2019344300
申请日：2019-09-19
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , LAMERIS ROELAND , DE GRUIJL TANJA DENISE , PARREN PAUL WILLEM HENRI IDA
IPC: C07K16/28 , A61K39/395 , A61P35/04
Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T- cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri-or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-,and tri-or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.
-
公开(公告)号：MX386714B
公开(公告)日：2025-03-11
申请号：MX2017009680
申请日：2017-07-26
Applicant: LAVA THERAPEUTICS N V
Inventor： VERHEUL HENDRIK MARINUS WILLEM , VAN DER VLIET JOHANNES JELLE , DE BRUIN RENÉE CORNELIA GERARDA , LAMERIS ROELAND , DE GRUIJL TANJA DENISE
Abstract: La presente invención se refiere a compuesto, en particular a polipéptidos que se unen específicamente a la proteína MHC no clásica CD1d y modulan las funciones biológicas mediadas por CD1d; la invención en particularmente relacionada a tales compuestos y polipéptidos que comprenden o consisten en al menos un anticuerpo de dominio simple se une específicamente a CD1d; también se proporcionan métodos y el uso empleando tales compuestos, polipéptidos y/o anticuerpos de dominio simple.
-
公开(公告)号：AU2016212777B2
公开(公告)日：2021-11-18
申请号：AU2016212777
申请日：2016-01-27
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , DE GRUIJL TANJA DENISE , VERHEUL HENDRIK MARINUS WILLEM , DE BRUIN RENEE CORNELIA GERARDA , LAMERIS ROLAND
IPC: C07K16/28
Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
-
Patent Agency Ranking
公开(公告)号：MX385333B
公开(公告)日：2025-03-18
申请号：MX2016013332
申请日：2016-10-10
Applicant: LAVA THERAPEUTICS N V
Inventor： VERHEUL HENDRIK MARINUS WILLEM , VAN DER VLIET JOHANNES JELLE , DE BRUIN RENÉE CORNELIA GERARDA , DE GRUIJL TANJA DENISE
Abstract: La presente invención se refiere a está en el campo de la medicina y se refiere a la inmunología, y se refiere en particular a moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas; las moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas son en particular para su uso en el tratamiento médico y/o útiles en pruebas con células T V?9Vd2 humanas, en donde la células T V?9Vd2 humanas pueden ser moduladas.
-
公开(公告)号：AU2022200922A1
公开(公告)日：2022-03-03
申请号：AU2022200922
申请日：2022-02-11
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , DE GRUIJL TANJA DENISE , VERHEUL HENDRIK MARINUS WILLEM , DE BRUIN RENÉE CORNELIA GERARDA , LAMERIS ROLAND
IPC: C07K16/28
Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CDd-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting 5 of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
-
公开(公告)号：AU2020216250A1
公开(公告)日：2021-08-26
申请号：AU2020216250
申请日：2020-01-30
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , DE WEERDT IRIS , DE GRUIJL TANJA DENISE , PARREN PAUL , KATER ARON PHILIP , SCHEFFER GEORGE LODEWIJK
Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
-
公开(公告)号：EA039086B1
公开(公告)日：2021-12-01
申请号：EA201692039
申请日：2015-04-10
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , DE BRUIN RENEE CORNELIA GERARDA , DE GRUIJL TANJA DENISE , VERHEUL HENDRIK MARINUS WILLEM
IPC: C07K16/28
Abstract: Изобретениеотноситсяк областимедициныи кобластииммунологии, ив частностиотноситсяк молекулеиммуноглобулина, связывающейчеловеческий V9V2 Т-клеточныйрецептор, нуклеотиднойпоследовательности, котораякодируетмолекулуиммуноглобулина, клетке-хозяину, содержащейуказаннуюнуклеотиднуюпоследовательность, способуполучениямолекулыиммуноглобулина, биспецифическомуантителу, применениюбиспецифическогоантителаприлечениирака, применениюмолекулыиммуноглобулинадляактивациичеловеческих V9V2 Т-клеток.
-
公开(公告)号：AU2015244489B2
公开(公告)日：2020-08-27
申请号：AU2015244489
申请日：2015-04-10
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , DE BRUIN RENEE CORNELIA GERARDA , DE GRUIJL TANJA DENISE , VERHEUL HENDRIK MARINUS WILLEM
IPC: C07K16/28
Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor bindingimmunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
